newsfilter
← Latest News
Business Wire·

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan

Japanese Product Now Under Review for Nationwide Marketing Approval Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's